FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium
Authors:
- Molly EasterMEMolly Easter
- Meghan June HirschMHMeghan June Hirsch
- Elex HarrisEHElex Harris
- Patrick Henry HowzePHPatrick Henry Howze
- Emma Lea MatthewsEMEmma Lea Matthews
- Luke I. JonesLJLuke I. Jones
- Seth BollenbeckerSBSeth Bollenbecker
- Shia VangSVShia Vang
- Daniel J. TyrrellDTDaniel J. Tyrrell
- Yan Y. SandersYSYan Y. Sanders
- Susan E. BirketSBSusan E. Birket
- Jarrod W. BarnesJBJarrod W. Barnes
Open Access
- 25 June 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (15)
Abstract
The number of adults living with cystic fibrosis (CF) has already increased significantly because of drastic improvements in life expectancy attributable to advances in treatment, including the development of highly effective modulator therapy. Chronic airway inflammation in CF contributes to morbidity and mortality, and aging processes like inflammaging and cell senescence influence CF pathology. Our results show that single-cell RNA sequencing data, human primary bronchial epithelial cells from non-CF and CF donors, a CF bronchial epithelial cell line, and Cftr -knockout ( Cftr –/– ) rats all demonstrated increased cell senescence markers in the CF bronchial epithelium. This was associated with upregulation of fibroblast growth factor receptors (FGFRs) and mitogen-activated protein kinase (MAPK) p38. Inhibition of FGFRs, specifically FGFR4 and to some extent FGFR1, attenuated cell senescence and improved mucociliary clearance, which was associated with MAPK p38 signaling. Mucociliary dysfunction could also be improved using a combination of senolytics in a CF ex vivo model. In summary, FGFR/MAPK p38 signaling contributes to cell senescence in CF airways, which is associated with impaired mucociliary clearance. Therefore, attenuation of cell senescence in the CF airways might be a future therapeutic strategy improving mucociliary dysfunction and lung disease in an aging population with CF.Keywords
Funding Information
- Division of Intramural Research (R01HL160911)
- Division of Intramural Research (R01HL152246)
- Division of Intramural Research (P30DK072482)
This publication has 64 references indexed in Scilit:
- Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerabilityEBioMedicine, 2023
- In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosisPharmacology Research & Perspectives, 2021
- A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesotheliomaLung Cancer, 2020
- Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot studyEBioMedicine, 2019
- Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyInvestigational New Drugs, 2017
- Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney diseaseKidney International, 2016
- Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular HypertrophyCell Metabolism, 2015
- Cellular senescence, ageing and diseaseAGE, 2008
- Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-Cell and tissue research, 2005
- Cellular signaling by fibroblast growth factor receptorsCytokine & Growth Factor Reviews, 2005